Did Select Medical beat or miss consensus estimates last quarter?

What guidance did Select Medical's management provide for the next earnings period?

What were the key takeaways from Select Medical’s earnings call?

What is the market's earnings forecast for Select Medical next quarter?

What is the revenue and EPS growth rate for Select Medical year over year?

What is Select Medical's gross profit margin?

What were the key takeaways from Select Medical's earnings call?

What does Select Medical do and what are its main business segments?

- **Expansion momentum**: Added 212 beds in 2025, with 399 beds expected by end-2027, driving inpatient rehab revenue growth.
- **Outpatient recovery**: 2026 outlook for outpatient EBITDA improvement, supported by 2% Medicare rate increase.
- **Financial discipline**: 2026 guidance reflects cautious optimism, with $520-540M EBITDA target.
- **Strategic focus**: Prioritizing inpatient rehab growth over share buybacks during take-private review.
- **Risk factors**: Higher health insurance costs ($15M Q4 impact) and competitive pressures in outpatient.


**【CEO Summary Section】**
- **Take-private proposal update**: The company received a nonbinding indication of interest to acquire all outstanding shares, with a special committee evaluating the proposal.
- **Inpatient rehab expansion**: Added 150 beds in Q4 (including 76-bed partnership with Vibra Healthcare) and 212 beds for the full year, with 399 beds expected by end-2027.
- **Financial highlights**: Total revenue grew 6% YoY to $1.2B, but adjusted EBITDA declined 10% to $104.7M due to higher health insurance expenses and lower net revenue per visit in outpatient.
- **Capital allocation**: Declared a $0.0625 dividend, maintaining focus on inpatient rehab growth.

**【CFO Financial Commentary】**
- **2025 financials**: Revenue up 5% to $5.4B, adjusted EBITDA of $493.2M (9% margin), and EPS of $1.16 (up 128% YoY).
- **2026 guidance**: Revenue $5.6-5.8B, adjusted EBITDA $520-540M, and EPS $1.22-1.32. Capital expenditures expected at $200-220M.
- **Balance sheet**: $1.8B debt outstanding, net leverage 3.67x, and $64.3M cash flow from operations in Q4.

**【Q&A Highlights】**
- **Outpatient challenges**: $11M impact from health insurance costs, variable discounts, and payer mix shift, with 2026 recovery expected.
- **Strategic alternatives**: No updates on take-private process, but focus on inpatient rehab growth.
- **Medicare rate changes**: 2% increase for 2026, expected to improve outpatient margins.
- **AI initiatives**: Piloting AI for outpatient collections and clinical applications like virtual sitters.
- **Labor trends**: Stable agency costs at 15% of workforce, with 56% labor margin in critical illness division.


Select Medical Holdings Corporation (SEM) Q4 2025 Earnings Call Transcript

- **Regulatory Relief Boosts Margins**: CMS' 20% transmittal rule deferment added $12-15 million to Q3 EBITDA, mitigating high-cost outlier impacts. 
- **Strong Development Momentum**: 395 new beds in inpatient rehab by mid-2027, including 76-bed Jersey City hospital, support 7% revenue growth. 
- **Outpatient Challenges**: Medicare cuts and payer mix shifts reduced outpatient EBITDA margin to 7.4%, but 2026 rate increases and productivity improvements aim to stabilize margins. 
- **Financial Discipline**: 3.4x net leverage and $175 million cash flow support dividend payments and strategic growth.

**【Management Opening Remarks】**
- CMS deferred the 20% transmittal rule implementation to October 2025, reducing its impact on critical illness recovery hospitals. This adjustment resulted in a $12-15 million EBITDA benefit for the quarter.
- The company announced new developments, including a 30-bed critical illness recovery hospital in Memphis and expansions in Texas, Florida, and New Jersey, adding 395 beds by mid-2027. A $0.0625 per share dividend was approved, reflecting commitment to shareholder returns.

**【CEO Commentary】**
- Total revenue grew 7% YoY to $1.36 billion, driven by 16% growth in inpatient rehab revenue and 4% in critical illness recovery. Adjusted EBITDA rose 7% to $111.7 million, with EPS increasing 21% to $0.23.
- Inpatient rehab segment showed strong performance: revenue up 16%, EBITDA up 13%, and occupancy improving to 83%. Outpatient segment faced challenges, with EBITDA margin declining to 7.4% due to Medicare cuts and payer mix shifts.

**【CFO Financial Commentary】**
- Debt stood at $1.8 billion with net leverage of 3.4x, stable and comfortable for operations. Cash flow from operations was $175.3 million, supporting development and dividend payments.
- Capital expenditures for 2025 were $180-200 million, with $100-105 million allocated to maintenance and the remainder to growth initiatives.

**【Q&A Highlights】**
- **Regulatory Environment**: CMS' 20% transmittal rule deferment reduced 2025 impact by 67%, but the fixed loss threshold for high-cost outliers rose to $79,000, affecting patient admissions. Advocacy efforts continue for policy reforms.
- **Development Pipeline**: 395 new beds in inpatient rehab by mid-2027, including partnerships with Cleveland Clinic and Banner Health. New hospitals in Texas, Florida, and New Jersey are expected to open by year-end.
- **Outpatient Challenges**: Medicare cuts and payer mix shifts caused EBITDA margin decline to 7.4%. Productivity improvements and system investments aim to stabilize margins in 2026.
- **Leverage and Capital Allocation**: Management prioritizes development, dividends, and debt reduction, with 3.4x leverage considered optimal for growth.

Select Medical Holdings Corporation (SEM) Q3 2025 Earnings Call Transcript

- **Revenue Growth & Expansion**: Q2 2025 revenue up 5% YoY to $1.3B, driven by 17% inpatient rehab growth. 382 new rehab beds planned by mid-2027.
- **Shareholder Returns**: $85.1M in share buybacks and $0.0625 dividend declared.
- **CIRH Challenges**: Q2 EBITDA down 22% YoY due to CMS reimbursement changes, but final rule for FY26 less punitive than proposed.
- **Outpatient Outlook**: EBITDA margin improved to 9.3%, targeting 10%+ in 2026 despite Medicare headwinds.
- **Policy Engagement**: CMS dialogue continues; industry faces 56% Medicare spend reduction since 2013 LTAC criteria.

**【CEO/Executive Chairman Remarks】**
- **Operational Highlights**: 8 of the company's hospitals were ranked among the nation's best, with Kessler Institute for Rehabilitation ranked #4. Q2 2025 saw the opening of 3 new hospitals and 8 outpatient clinics, with plans to add 382 rehab beds by mid-2027.
- **Financial Performance**: Revenue grew 5% YoY to $1.3B, adjusted EBITDA rose to $125.4M, and EPS increased 88% to $0.32. Inpatient rehab revenue grew 17% YoY to $313.8M, while critical illness recovery hospitals (CIRH) revenue declined 1% YoY to $601.1M due to reimbursement challenges.
- **Shareholder Returns**: $85.1M in share buybacks and a $0.0625 dividend declared, reflecting capital allocation focus.

**【CFO Financial Commentary】**
- **Balance Sheet**: $1.9B debt outstanding, $52.3M cash, and 3.57x net leverage. Q2 operating cash flow was $110.3M, with DSO at 62 days.
- **Guidance Update**: 2025 revenue expected $5.3B-$5.5B, adjusted EBITDA $510M-$530M, and EPS $1.09-$1.19. Capital expenditures narrowed to $180M-$200M.

**【Q&A Highlights】**
- **Critical Illness Recovery Hospitals (CIRH)**: Q2 EBITDA decline 22% YoY due to high-cost outlier threshold increases. CMS final rule for FY26 includes 2.9% rate increase and $1,188 outlier threshold hike, less punitive than proposed. Seasonality remains challenging, with Q1 typically strongest.
- **Outpatient Rehab**: EBITDA margin improved to 9.3% (from 9.1%), driven by patient volume growth and system upgrades. Targeting 10%+ margin in 2026 despite Medicare fee schedule headwinds.
- **Policy & Reimbursement**: Engaging with CMS on LTAC reforms; 20% transmittal rule remains in place. Industry-wide LTAC closures (24%) highlight reimbursement system strain.
- **Labor Costs**: Inpatient rehab labor inflation eased to 3% YoY, while CIRH costs rose slightly due to revenue pressures.

Select Medical Holdings Corporation (SEM) Q2 2025 Earnings Call Transcript

- **IRF Growth Engine**: 16% revenue growth, 440 new beds planned, and 85%+ occupancy expected despite expansion.
- **LTAC Regulatory Headwinds**: 25% EBITDA decline due to 100% outlier threshold increase; CMS proposed 2.7% rate hike for FY26.
- **Outpatient Recovery**: Q1 EBITDA decline offset by strong Q1 finish; 4%-6% commercial rate gains and 10 new clinics opened.
- **Balance Sheet Strength**: $377M revolving credit availability, 3.4x net leverage, and $11.4M stock buybacks in Q1.
- **2025 Outlook**: Revenue $5.3B-$5.5B, EBITDA $510M-$530M, EPS $1.09-$1.19, with capex $160M-$200M.

**【CEO Summary Section】**
- **Inpatient Rehab Division**: Q1 revenue grew 16%, EBITDA increased 15%, and 440 new beds are planned by end-2027. Key projects include a 63-bed hospital in Ozark, MO, and a 76-bed Kessler facility in Jersey City.
- **Outpatient Division**: Faced $4M weather impact and 3% Medicare rate decline, but ended Q1 strong with 1% revenue growth. 10 new clinics opened, offset by 13 closures.
- **Critical Illness Recovery Hospitals**: EBITDA declined 25% due to 100% increase in high-cost outlier threshold and 20% transmittal rule. CMS proposed 2.7% rate hike for FY26.
- **Development Pipeline**: 2025 plans include 45-bed hospital in Temple, TX, and 32-bed facility in Fairhill, OH. 2026 includes 63-bed hospital in Ozark, MO, and 76-bed Kessler in Jersey City.
- **Financial Highlights**: Revenue +2%, EBITDA -9% to $151.4M, EPS +33% to $0.44. Stock buybacks of $11.4M and dividend of $0.0625 declared.

**【CFO Financial Commentary】**
- **Debt & Liquidity**: $1.8B debt, 3.4x net leverage, $377.5M revolving credit availability. Interest expense down 28% to $29.1M.
- **Cash Flow**: Operating (-$3.5M), Investing (-$52.3M), Financing (+$49.3M). DSO 60 days.
- **2025 Guidance**: Revenue $5.3B-$5.5B, EBITDA $510M-$530M, EPS $1.09-$1.19. Capex $160M-$200M.

**【Q&A Key Takeaways】**
- **IRF Outlook**: Occupancy expected to stay above 85% despite new capacity. Mature hospitals consistently >85% occupied.
- **LTAC Mitigation**: Regulatory advocacy ongoing, but Q1 high-cost outlier impact (+100%) likely to ease post-respiratory season.
- **Outpatient Tech**: New software rolled out in Q1, driving 4%-6% commercial rate increases. Weather-impacted Q1 EBITDA would have exceeded prior year without storms.
- **Regulatory Risk**: CMS proposed rule for FY26 includes 2.4% IRF rate hike and 2.7% LTAC rate hike, final ruling expected late Q3.
- **Capital Allocation**: Prioritize stock buybacks, debt reduction, and development. $11.4M repurchased in Q1 at $17.52/share.

Select Medical (SEM)-2 May 25-2025 Q1 Earnings call transcript

- **Record Expansion**: 481 new beds (455 inpatient, 26 LTAC) planned for 2025-26, driving 30%+ inpatient capacity growth
- **Strong Financials**: Q4 2024 adjusted EBITDA up 4% to $116M; 2025 outlook for $520-540M EBITDA (+4%)
- **Debt Optimization**: 3.18x net leverage post-refinancing; targeting <3.0x by 2026
- **Division Performance**:
  - CIR: 10.5% EBITDA margin, 67% occupancy
  - Inpatient Rehab: 21.2% EBITDA margin (temporarily pressured by new bed openings)
  - Outpatient Rehab: 8.3% EBITDA margin, 18% growth
- **Key Risks**: Start-up losses (~$1M/Q4) in inpatient rehab, Medicare LTAC cuts

**【CEO Summary Section】**
- **Concentra Spin-Off Completion**: Q4 2024 revenue from continuing operations grew 8% YoY, with critical illness recovery (CIR) division revenue up 6% and adjusted EBITDA up 10%. 
- **Debt Restructuring**: Completed $1.6B debt refinancing, including $1.05B 7-year term loans at SOFR+2% and $550M senior notes. Net leverage improved to 3.18x vs. 3.6x pre-refinancing.
- **Bed Expansion**: Added 94 inpatient rehab beds in Q4, with 481 beds (455 inpatient, 26 LTAC) planned for 2025-26. Key projects include:
  - 60-bed rehab hospital in Southern NJ (Q4 2026)
  - 68-bed Castle facility in Jersey City (Q4 2026)
  - 58-bed facility in Tucson (Q1 2026)
- **Division Performance**:
  - CIR: 67% occupancy, 7% rate/day growth, 10.5% EBITDA margin
  - Inpatient Rehab: 81% occupancy, 6% rate/day growth, 21.2% EBITDA margin (down 4.3pts vs. prior year due to new facility start-up costs)
  - Outpatient Rehab: 7% revenue growth, 18% EBITDA growth, 8.3% margin

**【CFO Financial Commentary】**
- **Q4 2024 Financials**: 
  - Revenue: $1.4B (7% YoY growth)
  - Adjusted EBITDA: $116M (4% YoY growth)
  - Diluted EPS: -$0.19 (vs. $0.12 prior year)
- **Balance Sheet**: 
  - Total debt: $1.7B (3.18x net leverage)
  - Cash: $59.7M
  - Revolver availability: $453M
- **2025 Outlook**: 
  - Revenue: $5.4-5.6B (6% growth)
  - Adjusted EBITDA: $520-540M (4% growth)
  - EPS: $1.09-1.19
  - CapEx: $160-200M
- **Key Metrics**: 
  - DSO: 58 days (improving from 62 days in Q1 2024)
  - Nursing costs as % of revenue: 56.9% (down 0.7pts YoY)

**【Q&A Highlights】**
1. **Growth Drivers**:
   - Inpatient rehab: 30%+ bed growth over 24-26, targeting 20%+ EBITDA growth in 2026
   - Outpatient rehab: 10%+ EBITDA growth driven by rate increases and productivity gains
2. **Margin Pressures**:
   - Inpatient rehab start-up losses (~$1M/Q4) expected to persist in 2025
   - Medicare LTAC cuts offset by commercial rate increases
3. **Leverage Strategy**:
   - Target 3.0x-3.1x leverage in 2025, with deleveraging to <3.0x by 2026
   - Share buybacks contingent on development pipeline needs


Actual											0.1993	0.2046	0.3016	0.307	0.4416	0.657	0.307	0.1993	0.1993	0.2316	0.1131	0.1185	0.3016	0.3285	0.2477	0.1939	0.4147	0.3231	0.2693	0.18	0.44	0.32	0.23	0.16
Forecast											0.1699	0.0095	0.1573	0.1928	0.3268	0.3005	0.2816	0.1644	0.1484	0.2968	0.2424	0.194	0.2263	0.2903	0.219	0.1849	0.3057	0.3259	0.2237	0.1734	0.4469	0.2367	0.1547	0.2321
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+17.30%	+2053.68%	+91.74%	+59.23%	+35.13%	+118.64%	+9.02%	+21.23%	+34.30%	-21.97%	-53.34%	-38.92%	+33.27%	+13.16%	+13.11%	+4.87%	+35.66%	-0.86%	+20.38%	+3.81%	-1.54%	+35.19%	+48.67%	-31.06%

SEM

SEM fundamentals

SEM Q4 2025 Earnings

Earnings Call

You can ask Aime

SEM

SEM fundamentals

SEM Q4 2025 Earnings

Earnings Call

SEM Earnings Call Summary for Q4/20259:00 AM on Feb 20, 2026

SEM Earnings Call Summary for Q3/20259:00 AM on Oct 31, 2025

SEM Earnings Call Summary for Q2/20259:00 AM on Aug 1, 2025

SEM Earnings Call Summary for Q1/20259:00 AM on May 2, 2025

SEM Earnings Call Summary for Q4/20249:00 AM on Feb 21, 2025

You can ask Aime